Most men who have a heart attack in their forties or fifties were not obviously reckless. They were not all smokers, they were not all overweight, and a striking number had a cholesterol panel that their doctor had described as acceptable. Something was driving the disease that the standard test never looked for. In a meaningful proportion of those cases, that something is Lipoprotein(a), usually written Lp(a) and pronounced "L-P-little-a".

Lp(a) is one of the few cardiovascular risk factors that is almost entirely inherited, almost entirely stable across your lifetime, and almost never measured. It is not part of a routine lipid panel in Singapore or anywhere else by default. You have to ask for it, or choose a screening package that includes it. This guide explains what Lp(a) actually is, why it damages arteries through two separate mechanisms, who should be tested, and what a raised result should change about the way your cardiovascular risk is managed.

What Lipoprotein(a) actually is

To understand Lp(a) you first need a working picture of LDL, the particle everyone calls "bad cholesterol". LDL is a spherical package of fat wrapped in a protein shell, and its job is to ferry cholesterol from the liver to tissues that need it. The single structural protein wrapped around each LDL particle is called apolipoprotein B, or apoB. When people talk about LDL cholesterol they are really talking about the cholesterol cargo carried inside these apoB particles.

Lp(a) is an LDL particle with one extra component bolted on. A second protein, apolipoprotein(a) or apo(a), is covalently attached to the apoB shell. That single addition changes the particle's behaviour completely. Apo(a) is sticky, it is inflammatory, and it happens to look structurally very similar to a protein your body uses to dissolve blood clots. The result is a particle that behaves like LDL when it comes to clogging arteries, and like a clot-promoting agent on top of that.

The quantity of Lp(a) in your blood is set almost entirely by the LPA gene you inherited. Estimates from twin and family studies put the heritability above ninety percent. Unlike LDL cholesterol, which swings with diet, weight, alcohol, thyroid function and medication, your Lp(a) concentration is broadly fixed from childhood and stays within a narrow band for the rest of your life. This has one enormously practical consequence: you only need to measure it once.

Why Lp(a) is a dual threat to your arteries

Elevated Lp(a) is not merely associated with heart disease. Mendelian randomisation studies, which use inherited genetic variation as a natural experiment, have shown the relationship is causal. People who inherit variants producing high Lp(a) develop more atherosclerotic disease, and the effect is independent of LDL cholesterol, blood pressure, smoking and diabetes. Two mechanisms explain it.

It accelerates plaque formation

Lp(a) crosses into the artery wall as readily as LDL does, but it is retained there more aggressively. The apo(a) tail binds strongly to the connective tissue matrix inside the vessel wall, so particles that enter tend to stay. Worse, Lp(a) is the main carrier of oxidised phospholipids in human plasma. These are potent inflammatory signals. Once trapped in the arterial wall, an Lp(a) particle does not just deposit cholesterol, it actively recruits immune cells and drives the inflammatory cascade that turns a fatty streak into a plaque capable of rupturing.

It interferes with clot breakdown

The second mechanism is the more insidious one. Apo(a) is structurally homologous to plasminogen, the precursor of the enzyme that dissolves fibrin clots. By resembling plasminogen closely enough to occupy its binding sites without doing its job, Lp(a) blunts the body's natural clot-clearing machinery. A plaque that ruptures in someone with high Lp(a) is therefore more likely to produce a clot that persists and occludes the vessel rather than one that is broken down before it causes damage. This is why high Lp(a) is linked not only to coronary disease but to ischaemic stroke and to calcific aortic valve stenosis.

How common is high Lp(a)

Roughly one in five people worldwide carries an Lp(a) level in the range considered clinically significant. That is well over a billion individuals, the overwhelming majority of whom have never heard of the marker, let alone been tested for it.

Distribution varies by ancestry, and this matters in Singapore's multi-ethnic population. Population studies consistently show that people of South Asian descent tend to carry higher median Lp(a) levels than people of Chinese descent, with people of Malay and other Southeast Asian ancestry falling in between. This is one plausible contributor to the long-documented excess of premature coronary artery disease in South Asian men, a pattern seen in Singapore's own cardiovascular statistics and one that is not fully explained by diabetes, smoking or conventional lipids.

If your family tree includes a father, uncle or brother who had a heart attack before sixty, and nobody could quite explain why, Lp(a) is one of the first things worth ruling in or out.

Interpreting your Lp(a) result

Lp(a) is reported either as a mass concentration in milligrams per decilitre or as a particle concentration in nanomoles per litre. The two are not interchangeable and cannot be converted reliably, because the apo(a) protein varies in size between individuals. Where you have a choice, the nmol/L measurement is the more robust one. A widely used framework is roughly as follows:

Lp(a) level	Interpretation	Practical meaning
Below 30 mg/dL (about 75 nmol/L)	Desirable	No additional risk attributable to Lp(a)
30 to 50 mg/dL (75 to 125 nmol/L)	Borderline	Treat as a risk enhancer alongside other factors
50 to 90 mg/dL (125 to 225 nmol/L)	High	Meaningful independent risk, intensify management
Above 90 mg/dL (above 225 nmol/L)	Very high	Substantial risk, aggressive management and family testing

Once a level passes 50 mg/dL (about 125 nmol/L), the risk it carries is independent of LDL cholesterol, meaning it persists after accounting for cholesterol, blood pressure, smoking and diabetes. In the Copenhagen City Heart Study, which followed 9,330 adults for about a decade, the adjusted risk of heart attack rose from roughly 1.6 times at 30 to 84 mg/dL, to roughly 2.6 times at 85 to 119 mg/dL, and to roughly 3.6 times at 120 mg/dL and above, compared with people below 5 mg/dL.

These thresholds describe risk on a continuum, not a switch. There is no level above which disaster is certain and none below which you are protected from every other cardiovascular risk factor. What a high number does is shift the calculation. A man with an Lp(a) of 200 nmol/L and an otherwise middling risk profile is not a middling risk patient, and should not be managed as one.

One caveat worth knowing: Lp(a) is an acute phase reactant to a modest degree, meaning it can rise transiently during significant inflammation, infection or after a heart attack. If a result is measured during acute illness and comes back borderline, repeating it once you are well is reasonable. Otherwise, one lifetime measurement is enough.

Who should be tested

Major cardiology bodies, including the European Atherosclerosis Society, now recommend that every adult have their Lp(a) measured at least once in their lifetime. Universal one-time testing is the direction of travel. In practice, testing is most urgent if any of the following applies to you:

A personal history of heart attack, stroke, angina or coronary stenting, particularly if it occurred before sixty.
A first-degree relative who developed cardiovascular disease early, meaning before fifty-five in men or sixty-five in women.
A known family history of familial hypercholesterolaemia, or an LDL cholesterol that has always run unusually high.
Calcific aortic valve disease, especially if diagnosed at a relatively young age.
A borderline or intermediate ten-year cardiovascular risk score, where the result would tip the decision on whether to start lipid-lowering treatment.
A close relative already known to have a high Lp(a).

The case for cascade screening

Because Lp(a) is inherited in a codominant fashion, a high result in you means each of your parents, siblings and children has approximately a fifty percent chance of carrying the same elevation. Testing them is cheap, requires a single blood draw, and can identify people who need aggressive prevention decades before they would otherwise present. Cascade screening turns one abnormal result into a family-wide prevention programme, and it is probably the single highest-yield action a person with high Lp(a) can take.

What to do about a high Lp(a)

The uncomfortable truth about today's options

There is currently no licensed drug whose primary purpose is lowering Lp(a). Statins, the backbone of lipid management, do not lower it and may raise it very slightly, though this does not offset their clear net benefit and is never a reason to stop them. Niacin lowers Lp(a) but has not shown outcome benefit and carries side effects. PCSK9 inhibitors lower Lp(a) by roughly a quarter as a secondary effect, which is useful but rarely sufficient on its own. Lipoprotein apheresis, a filtration procedure, is effective but reserved for extreme cases.

So the current strategy is not to chase the Lp(a) number itself. It is to treat the high Lp(a) as a permanent, unmodifiable multiplier on your total cardiovascular risk, and then to drive every modifiable factor as low as it will reasonably go. In practice that means:

LDL cholesterol treated to a lower target than your risk score alone would suggest. This is the single most effective lever, and for many people with high Lp(a) it means starting a statin earlier or at a higher intensity, sometimes with ezetimibe added.
Blood pressure genuinely controlled, not simply monitored year after year while it drifts upwards.
Complete smoking and vaping cessation. The combination of high Lp(a) and smoking is particularly dangerous given both promote thrombosis.
Diabetes and insulin resistance addressed early, since metabolic disease compounds arterial injury.
Structured exercise and weight management, which do not lower Lp(a) but substantially lower the risk it is amplifying.
A conversation about aspirin, which in some people with high Lp(a) and additional risk factors may be appropriate given the pro-thrombotic mechanism. This is an individual decision that needs a doctor, not a blanket recommendation.

What is coming

This is one of the genuinely exciting areas in cardiovascular medicine. A new generation of therapies using antisense oligonucleotides and small interfering RNA targets apo(a) production in the liver directly, and early trials have reported Lp(a) reductions of eighty to ninety percent with infrequent dosing. Large outcome trials are underway to establish whether lowering the number translates into fewer heart attacks and strokes. If they read out positively, universal Lp(a) testing will move from a recommendation to a standard of care very quickly. Knowing your number now means you will be ready.

Testing for Lp(a) in Singapore

Lp(a) is a straightforward blood test that does not require fasting and can be added to a standard lipid panel from the same draw. It is not included in most basic screening packages by default, so you generally need to request it or select a package that covers advanced cardiovascular markers.

The number in isolation is of limited value. What makes the test worthwhile is interpreting it alongside your apoB, your LDL particle count, hs-CRP, blood pressure, glucose handling and family history, and then converting that picture into a concrete plan with a review date. At our Orchard clinic, Lp(a) is included in the advanced cardiovascular assessment within our comprehensive screening tiers, and results are reviewed with a doctor rather than emailed as a number on a page.

Frequently Asked Questions about Lipoprotein(a)

Q: Is Lp(a) included in a normal cholesterol test in Singapore?

A: No. A standard lipid panel reports total cholesterol, LDL, HDL and triglycerides, and Lp(a) is not among them. It has to be requested specifically or come as part of an advanced cardiovascular panel. This is why so many people with high Lp(a) go their entire lives without knowing, even after multiple health screenings that they were told were normal.

Q: How often should Lp(a) be retested?

A: For most people, once is enough. Because levels are over ninety percent genetically determined and stable through adult life, repeating the test annually adds nothing. The exceptions are a borderline result taken during acute illness, pregnancy, significant kidney disease or thyroid dysfunction, where a single repeat once things have settled is reasonable.

Q: Can diet or exercise lower my Lp(a)?

A: Not meaningfully. Unlike LDL cholesterol and triglycerides, which respond well to diet, weight loss and exercise, Lp(a) is largely unmoved by lifestyle change. That is not an argument against those measures, it is the opposite. Because you cannot lower the Lp(a) itself, lowering everything else becomes more important, not less.

Q: Do statins lower Lp(a)?

A: No, and in some studies statins raise Lp(a) marginally. This is not a reason to avoid or stop them. Statins remain the most effective way to reduce the LDL burden that is compounding your Lp(a) risk, and their overall benefit in people with high Lp(a) is clear. The right response to a high Lp(a) is usually more aggressive LDL lowering, not less.

Q: My Lp(a) is high but I feel completely fine. Do I need to do anything now?

A: Feeling fine is expected. Atherosclerosis is silent for decades and produces no symptoms until a plaque ruptures or an artery narrows enough to limit blood flow. A high Lp(a) in a symptom-free person is precisely the situation prevention is designed for, because you still have time to change the trajectory. What it should trigger is a full risk assessment, a plan for LDL and blood pressure, and testing for your immediate family.

Q: Should my children be tested?

A: If your Lp(a) is high, each of your children has roughly a fifty percent chance of inheriting the same elevation, so testing them at some point in adulthood is sensible. Testing in childhood is generally reserved for families with familial hypercholesterolaemia or very early cardiovascular disease, and is a decision to make with a doctor rather than a default.

Book a cardiac risk assessment at our Orchard clinic or speak to a doctor about adding Lp(a) to your next screening.

References

Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184. https://pubmed.ncbi.nlm.nih.gov/18086931/
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925-3946. https://pubmed.ncbi.nlm.nih.gov/36036785/
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020;41(1):111-188. https://pubmed.ncbi.nlm.nih.gov/31504418/

Understanding Lipoprotein(a): The Inherited Heart Risk Most Singaporeans Never Test For